Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naive Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe.

ABSTRACT: Dolutegravir (DTG) use in combination with tenofovir and lamivudine (TLD) is scaling up in Africa. However, HIV drug resistance (HIVDR) data to DTG remain scarce in Zimbabwe. We assessed the prevalence and genetic mechanisms of DTG resistance in people living with HIV initiating on TLD. A prospective cohort study was conducted between October 2021 and April 2023 among antiretroviral therapy (ART) naïve adults (≥18 years) attending care at an HIV clinic in Zimbabwe. Pre-treatment drug resistance (PDR) was assessed prior to TLD initiation and viral load (VL) outcome and acquired drug resistance (ADR) to TLD were described after 24 weeks follow-up. In total, 172 participants were enrolled in the study. The median (IQR) age and log₁₀ VL were 39 (29-48) years and 5.41 (4.80-5.74) cop

SUBMITTER: Kouamou V 

PROVIDER: S-EPMC10534864 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature